var data={"title":"Lentigo maligna: Clinical manifestations, diagnosis, and management","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Lentigo maligna: Clinical manifestations, diagnosis, and management</div><dl id=\"topicContributors\"><dt><span> </span>Authors:</dt><dd><a href=\"https://www.uptodate.com/contents/lentigo-maligna-clinical-manifestations-diagnosis-and-management/contributors\" class=\"contributor contributor_credentials\">Arthur J Sober, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/lentigo-maligna-clinical-manifestations-diagnosis-and-management/contributors\" class=\"contributor contributor_credentials\">Suzanne Olbricht, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/lentigo-maligna-clinical-manifestations-diagnosis-and-management/contributors\" class=\"contributor contributor_credentials\">Hensin Tsao, MD, PhD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/lentigo-maligna-clinical-manifestations-diagnosis-and-management/contributors\" class=\"contributor contributor_credentials\">Rosamaria Corona, MD, DSc</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/lentigo-maligna-clinical-manifestations-diagnosis-and-management/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Jun 09, 2015.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H244299021\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Lentigo maligna (LM) is a type of melanoma in situ that typically occurs in sun-damaged skin of the face and neck of older individuals [<a href=\"https://www.uptodate.com/contents/lentigo-maligna-clinical-manifestations-diagnosis-and-management/abstract/1\" class=\"abstract_t\">1</a>]. LM evolves slowly over many years and may progress to invasive lentigo maligna melanoma. &quot;Hutchinson melanotic freckle&quot; and &quot;melanosis circumscripta precancerosa of Dubreuilh&quot; are synonyms of LM [<a href=\"https://www.uptodate.com/contents/lentigo-maligna-clinical-manifestations-diagnosis-and-management/abstract/2,3\" class=\"abstract_t\">2,3</a>]. </p><p>This topic will discuss the clinical features, diagnosis, and treatment of lentigo maligna. Lentigo maligna melanoma is discussed separately. (See <a href=\"topic.htm?path=melanoma-clinical-features-and-diagnosis#H81531027\" class=\"medical medical_review\">&quot;Melanoma: Clinical features and diagnosis&quot;, section on 'Lentigo maligna melanoma'</a> and <a href=\"topic.htm?path=pathologic-characteristics-of-melanoma#H9\" class=\"medical medical_review\">&quot;Pathologic characteristics of melanoma&quot;, section on 'Lentigo maligna melanoma'</a>.)</p><p class=\"headingAnchor\" id=\"H244299028\"><span class=\"h1\">EPIDEMIOLOGY AND NATURAL HISTORY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Lentigo maligna (LM) usually occurs in older individuals with a peak incidence between 65 and 80 years [<a href=\"https://www.uptodate.com/contents/lentigo-maligna-clinical-manifestations-diagnosis-and-management/abstract/4,5\" class=\"abstract_t\">4,5</a>]. The incidence of LM appears to be increasing in younger age groups. One study reported a 52 percent increase in the incidence rate of LM among men and women aged 45 to 64 years between 1990 and 2000 in the United States [<a href=\"https://www.uptodate.com/contents/lentigo-maligna-clinical-manifestations-diagnosis-and-management/abstract/6\" class=\"abstract_t\">6</a>]. Another population study reported an increase in incidence from 2.2 per 100,000 per year between 1970 and 1989 to 13.7 per 100,000 per year between 2004 and 2007 in the United States [<a href=\"https://www.uptodate.com/contents/lentigo-maligna-clinical-manifestations-diagnosis-and-management/abstract/7\" class=\"abstract_t\">7</a>]. The risk of LM and lentigo maligna melanoma is higher in fair skinned individuals with markers of actinic skin damage (solar lentigines and actinic keratoses) and a history of nonmelanoma skin cancer [<a href=\"https://www.uptodate.com/contents/lentigo-maligna-clinical-manifestations-diagnosis-and-management/abstract/8,9\" class=\"abstract_t\">8,9</a>].</p><p>LM is a slowly evolving lesion and is often diagnosed years or decades after its occurrence. In some lesions, partial central regression may occur while the peripheral margin continues to extend [<a href=\"https://www.uptodate.com/contents/lentigo-maligna-clinical-manifestations-diagnosis-and-management/abstract/10,11\" class=\"abstract_t\">10,11</a>]. The time to progression of LM to invasive lentigo maligna melanoma ranges from less than 10 to more than 50 years [<a href=\"https://www.uptodate.com/contents/lentigo-maligna-clinical-manifestations-diagnosis-and-management/abstract/10,12\" class=\"abstract_t\">10,12</a>]. </p><p>The lifetime risk of progression of lentigo maligna to a lentigo maligna melanoma was estimated to be about 5 percent [<a href=\"https://www.uptodate.com/contents/lentigo-maligna-clinical-manifestations-diagnosis-and-management/abstract/13\" class=\"abstract_t\">13</a>]. However, these data are old and in some series, up to 20 percent of patients undergoing excision for LM were found to have invasive disease [<a href=\"https://www.uptodate.com/contents/lentigo-maligna-clinical-manifestations-diagnosis-and-management/abstract/14-17\" class=\"abstract_t\">14-17</a>]. </p><p class=\"headingAnchor\" id=\"H244299035\"><span class=\"h1\">CLINICAL FEATURES</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Lentigo maligna (LM) usually presents as an atypical pigmented macular lesion localized on severely sun-damaged skin of the head or neck. Clinical features of LM include (<a href=\"image.htm?imageKey=DERM%2F62052%7EDERM%2F59591%7EDERM%2F68787%7EDERM%2F75238%7EDERM%2F77206\" class=\"graphic graphic_picture graphicRef62052 graphicRef59591 graphicRef68787 graphicRef75238 graphicRef77206 \">picture 1A-E</a>):</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Irregular shape </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Variable color, from light brown or tan to dark brown, black, pink, red, or white </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Variable size, from less than one to several centimeters</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Non-scaly, smooth surface</p><p/><p>Pink or white areas indicate inflammation or regression. The nose, cheeks, and ears are preferentially involved. Infrequently, LM occurs in non-head and neck locations such as the upper back, forearms, and legs. The surrounding skin typically shows evidence of chronic solar damage (solar elastosis, solar lentigines, or actinic keratoses). The borders may be ill-defined. Because of radial growth and regression phenomena, at times LM appears to be moving across the skin. Amelanotic LM is rare [<a href=\"https://www.uptodate.com/contents/lentigo-maligna-clinical-manifestations-diagnosis-and-management/abstract/18,19\" class=\"abstract_t\">18,19</a>]. </p><p>The development of darker pigmentation, sharper borders, or elevated or nodular areas are clinical signs of progression to lentigo maligna melanoma (LMM) (<a href=\"image.htm?imageKey=PC%2F62105%7EDERM%2F57765%7EDERM%2F74664%7EDERM%2F54753\" class=\"graphic graphic_picture graphicRef62105 graphicRef57765 graphicRef74664 graphicRef54753 \">picture 2A-D</a>). Rarely, a desmoplastic melanoma may develop within an LM, presenting as a central firm thickening that is reminiscent of a scar. (See <a href=\"topic.htm?path=pathologic-characteristics-of-melanoma#H14\" class=\"medical medical_review\">&quot;Pathologic characteristics of melanoma&quot;, section on 'Desmoplastic melanoma'</a>.)</p><p class=\"headingAnchor\" id=\"H2436682\"><span class=\"h1\">DERMOSCOPIC FEATURES</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In skin areas other than face, the pigment network seen by dermoscopy is the main criterion in determining whether a pigmented lesion is melanocytic and evaluating whether it is benign or malignant [<a href=\"https://www.uptodate.com/contents/lentigo-maligna-clinical-manifestations-diagnosis-and-management/abstract/20\" class=\"abstract_t\">20</a>]. (See <a href=\"topic.htm?path=overview-of-dermoscopy\" class=\"medical medical_review\">&quot;Overview of dermoscopy&quot;</a> and <a href=\"topic.htm?path=dermoscopic-evaluation-of-skin-lesions\" class=\"medical medical_review\">&quot;Dermoscopic evaluation of skin lesions&quot;</a>.)</p><p>Because of the unique features of facial skin (absence or flattening of rete ridges and increased number and prominence of hair follicles and sweat gland ostia), pigmented lesions occurring on the face do not show a pigment network when examined with a dermatoscope. In contrast, the distribution of the pigmentation around the prominent hair follicles forms a pseudonetwork that is seen in both melanocytic and nonmelanocytic lesions (eg, seborrheic keratoses) [<a href=\"https://www.uptodate.com/contents/lentigo-maligna-clinical-manifestations-diagnosis-and-management/abstract/21\" class=\"abstract_t\">21</a>]. (See <a href=\"topic.htm?path=dermoscopy-of-facial-lesions\" class=\"medical medical_review\">&quot;Dermoscopy of facial lesions&quot;</a>.)</p><p>Since the pseudonetwork does not discriminate melanocytic from nonmelanocytic lesions, other dermoscopic criteria are used for the diagnosis of facial lesions. Horn pseudocysts, yellow opaque areas, fingerprint-like structures, moth-eaten pattern and jelly sign suggest solar lentigo or flat seborrheic keratosis, whereas the features most frequently seen in lentigo maligna (LM) and lentigo maligna melanoma include (<a href=\"image.htm?imageKey=DERM%2F63812%7EDERM%2F68828\" class=\"graphic graphic_picture graphicRef63812 graphicRef68828 \">picture 3A-B</a>) [<a href=\"https://www.uptodate.com/contents/lentigo-maligna-clinical-manifestations-diagnosis-and-management/abstract/22\" class=\"abstract_t\">22</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Asymmetric pigmented follicular openings (atypical pseudonetwork)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Dark rhomboidal structures</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Annular-granular pattern </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Gray pseudonetwork</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Slate gray areas</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Slate-grey dots and globules</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Streaks </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Black blotches</p><p/><p>However, these features may be also seen in pigmented actinic keratosis, an unusual variant of actinic keratosis that is difficult to differentiate from LM on clinical and dermoscopic examination [<a href=\"https://www.uptodate.com/contents/lentigo-maligna-clinical-manifestations-diagnosis-and-management/abstract/23\" class=\"abstract_t\">23</a>]. One study found that four dermoscopic features have high sensitivity and specificity (89 and 96 percent, respectively) for the diagnosis of lentigo maligna (LM) or lentigo maligna melanoma (LMM) (<a href=\"image.htm?imageKey=DERM%2F68828%7EDERM%2F63812\" class=\"graphic graphic_picture graphicRef68828 graphicRef63812 \">picture 3A-B</a>) [<a href=\"https://www.uptodate.com/contents/lentigo-maligna-clinical-manifestations-diagnosis-and-management/abstract/24\" class=\"abstract_t\">24</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Asymmetrical pigmented follicular openings (atypical pseudonetwork)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Dark rhomboidal structures</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Slate-gray globules </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Slate-gray dots</p><p/><p>Another study found that, irrespective of the specific dermoscopic pattern seen in a lesion, the presence of gray color, seen in approximately 90 percent of cases, was the single most important criterion in the diagnosis of LM [<a href=\"https://www.uptodate.com/contents/lentigo-maligna-clinical-manifestations-diagnosis-and-management/abstract/25\" class=\"abstract_t\">25</a>]. Although dermoscopy is helpful in the clinical diagnosis of benign facial lesions such as solar lentigines and seborrheic keratoses, biopsy and histopathology evaluation remain the gold standard for the diagnosis of LM or pigmented actinic keratosis. Lesions showing dermoscopic features suspicious of LM should be biopsied for histopathologic confirmation. For large LM lesions requiring incisional biopsy for the initial diagnosis, dermoscopy may be useful in targeting areas with the most atypical findings for biopsy. (See <a href=\"#H244299049\" class=\"local\">'Biopsy and histologic examination'</a> below.)</p><p class=\"headingAnchor\" id=\"H244299042\"><span class=\"h1\">HISTOPATHOLOGIC FEATURES</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Histologically, lentigo maligna (LM) is characterized by an increased number of atypical melanocytes, often spindle shaped, arranged in single cells or in small nests along the dermoepidermal junction, often extending into the infundibular portion of hair follicles (<a href=\"image.htm?imageKey=DERM%2F60447%7EONC%2F53790\" class=\"graphic graphic_picture graphicRef60447 graphicRef53790 \">picture 4A-B</a>) [<a href=\"https://www.uptodate.com/contents/lentigo-maligna-clinical-manifestations-diagnosis-and-management/abstract/12\" class=\"abstract_t\">12</a>]. Melanocytic atypia ranges from near normal to multinucleated melanocytes or melanocytes with dendritic processes [<a href=\"https://www.uptodate.com/contents/lentigo-maligna-clinical-manifestations-diagnosis-and-management/abstract/26\" class=\"abstract_t\">26</a>]. Cytoplasm retraction artifacts may be seen. </p><p>Changes of chronic solar damage usually coexist, including elastosis, atrophy of the epidermis, effacement of rete ridges, and inflammatory dermal infiltrate [<a href=\"https://www.uptodate.com/contents/lentigo-maligna-clinical-manifestations-diagnosis-and-management/abstract/12\" class=\"abstract_t\">12</a>]. Determining the histologically clear margin of LM is particularly difficult because the transition between LM and melanocytic hyperplasia of sun-damaged skin is often subtle. A biopsy specimen of normal appearing but sun-damaged skin, taken as a control, may aid in this distinction since it provides a reference for the background level of melanocytic hyperplasia in a given individual [<a href=\"https://www.uptodate.com/contents/lentigo-maligna-clinical-manifestations-diagnosis-and-management/abstract/27\" class=\"abstract_t\">27</a>].</p><p>Immunostaining with HMB-45 and MART-1 may be used to assist in diagnosis. </p><p>Most pathologists consider all LM lesions without evidence of dermal invasion as melanoma in situ. In contrast, some pathologists distinguish a premalignant LM from true melanoma in situ of lentigo maligna type (LMMIS) on the basis of the growth pattern of atypical melanocytes [<a href=\"https://www.uptodate.com/contents/lentigo-maligna-clinical-manifestations-diagnosis-and-management/abstract/28\" class=\"abstract_t\">28</a>]. LMMIS is characterized by pagetoid spread of atypical cells involving the full thickness of the epidermis, whereas LM shows a less continuous lentiginous proliferation, lower cellularity, and less than full thickness pagetoid spread of atypical melanocytes [<a href=\"https://www.uptodate.com/contents/lentigo-maligna-clinical-manifestations-diagnosis-and-management/abstract/28\" class=\"abstract_t\">28</a>]. (See <a href=\"topic.htm?path=pathologic-characteristics-of-melanoma#H4\" class=\"medical medical_review\">&quot;Pathologic characteristics of melanoma&quot;, section on 'In situ melanoma'</a>.)</p><p>Regardless, the treatment approach is not influenced by the histologic interpretation of LM as a premalignant melanoma precursor or a true melanoma in situ, since complete surgical excision is recommended for all LM lesions where possible. (See <a href=\"#H244299056\" class=\"local\">'Treatment'</a> below.)</p><p class=\"headingAnchor\" id=\"H20157199\"><span class=\"h1\">DIAGNOSIS</span></p><p class=\"headingAnchor\" id=\"H1146732\"><span class=\"h2\">Clinical and dermoscopic examination</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The diagnosis of lentigo maligna (LM) is based upon clinical, dermoscopic, and histologic examination. (See <a href=\"#H244299035\" class=\"local\">'Clinical features'</a> above and <a href=\"#H2436682\" class=\"local\">'Dermoscopic features'</a> above and <a href=\"#H244299042\" class=\"local\">'Histopathologic features'</a> above.)</p><p>The clinical diagnosis of lentigo maligna at an early stage may be difficult even for the experienced dermatologist. On clinical examination, the recognition of LM is often complicated by the presence of multiple lesions that are similar in appearance, including solar lentigines, flat seborrheic keratoses, and actinic keratoses. </p><p>Dermoscopy may be helpful in differentiating early LM from benign pigmented lesions occurring on sun-damaged skin such as seborrheic keratoses and solar lentigines. However, differentiating a pigmented actinic keratosis from LM by dermoscopy is difficult and not always possible. Pigmented actinic keratoses are a rare variant of actinic keratosis that share clinical and dermoscopic features with LM. (See <a href=\"#H2436682\" class=\"local\">'Dermoscopic features'</a> above and <a href=\"#H20157231\" class=\"local\">'Differential diagnosis'</a> below.)</p><p class=\"headingAnchor\" id=\"H60107460\"><span class=\"h2\">Confocal scanning laser microscopy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Confocal scanning laser microscopy (CSLM) is a noninvasive, complex technique for the imaging of human skin, with cellular resolution deep to the papillary dermis. CSLM has been evaluated in a small number of patients for the differentiation of LM from other pigmented lesions of the face [<a href=\"https://www.uptodate.com/contents/lentigo-maligna-clinical-manifestations-diagnosis-and-management/abstract/29-31\" class=\"abstract_t\">29-31</a>]. However, CSLM is available only at specialized dermatologic institutions and data on its diagnostic accuracy are limited [<a href=\"https://www.uptodate.com/contents/lentigo-maligna-clinical-manifestations-diagnosis-and-management/abstract/32\" class=\"abstract_t\">32</a>].</p><p class=\"headingAnchor\" id=\"H244299049\"><span class=\"h2\">Biopsy and histologic examination</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Biopsy is necessary to establish the diagnosis of LM. Excisional biopsy with narrow margins is ideal, although a saucerization (deep shave) may be adequate in some cases. Since abnormal melanocytic cells may extend down the adventitia of the hair follicles, a more superficial shave is not adequate since it may not include this area for evaluation. </p><p>For LMs that are broad and located on cosmetically sensitive sites, partial biopsy (punch or incisional biopsy) may be performed. However, considerable sampling errors can occur with partial biopsies because the histopathologic findings may vary within the lesion. Evidence of dermal invasion has been reported in up to 20 percent of specimens with a preoperative diagnosis of LM on initial biopsy [<a href=\"https://www.uptodate.com/contents/lentigo-maligna-clinical-manifestations-diagnosis-and-management/abstract/14-17\" class=\"abstract_t\">14-17</a>]. </p><p>The choice of the site(s) for incisional biopsy is based upon clinical examination and dermoscopy. The most irregular or heavily pigmented areas identified by clinical <span class=\"nowrap\">and/or</span> dermoscopic examination and any palpable or thickened areas are the preferred biopsy sites.</p><p>Histologically, the replacement of basal keratinocytes by atypical melanocytes with background changes of chronic sun damage (epidermal atrophy, effacement of rete ridges, and inflammatory dermal infiltrate) is diagnostic of LM. Microscopic features of benign solar lentigo, LM, and lentigo maligna melanoma (LMM) may coexist in the same lesion. (See <a href=\"#H244299042\" class=\"local\">'Histopathologic features'</a> above.)</p><p class=\"headingAnchor\" id=\"H20157231\"><span class=\"h1\">DIFFERENTIAL DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Lentigo maligna (LM) should be differentiated from other melanocytic and nonmelanocytic lesions, including:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Solar lentigo</strong> &ndash; Solar lentigines are large, macular lesions with irregular margins and uniform brown pigmentation. Solar lentigines are commonly seen on chronically sun-exposed sites (face, dorsum of hands) of older individuals with fair skin and a history of excessive sun exposure (<a href=\"image.htm?imageKey=DERM%2F81287%7EDERM%2F61452\" class=\"graphic graphic_picture graphicRef81287 graphicRef61452 \">picture 5A-B</a>). In contrast with solar lentigines, the macular lesions of LM tend to be darker and irregularly pigmented. Histologically, solar lentigo is characterized by a linear increase of melanocytes at the dermal&ndash;epidermal junction, in the absence of cytologic atypia. (See <a href=\"topic.htm?path=benign-pigmented-skin-lesions-other-than-melanocytic-nevi-moles#H5\" class=\"medical medical_review\">&quot;Benign pigmented skin lesions other than melanocytic nevi (moles)&quot;, section on 'Solar lentigo'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Pigmented actinic keratosis</strong> &ndash; Pigmented actinic keratoses present as scaly, hyperpigmented macules or patches occurring on sun-exposed skin of adult individuals with fair complexion. Pigmented actinic keratoses are difficult to differentiate from LM by naked eye or dermoscopic examination. Histologically, there is a proliferation of atypical keratinocytes extending from the basal layer upward, with increased melanin in the lower epidermis and dermal melanophages. (See <a href=\"topic.htm?path=epidemiology-natural-history-and-diagnosis-of-actinic-keratosis#H17075261\" class=\"medical medical_review\">&quot;Epidemiology, natural history, and diagnosis of actinic keratosis&quot;, section on 'Clinical features'</a> and <a href=\"topic.htm?path=epidemiology-natural-history-and-diagnosis-of-actinic-keratosis#H625419\" class=\"medical medical_review\">&quot;Epidemiology, natural history, and diagnosis of actinic keratosis&quot;, section on 'Pathology'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Seborrheic keratosis</strong> &ndash; Seborrheic keratoses are common benign keratinocytic tumors presenting as macular or elevated lesions, with variable brown pigmentation and a dull surface (<a href=\"image.htm?imageKey=DERM%2F58445\" class=\"graphic graphic_picture graphicRef58445 \">picture 6</a>). On the face, seborrheic keratoses may remain superficial for a long period. Dermoscopic examination is helpful in differentiating seborrheic keratosis from LM. Histologically, there is a proliferation of normal keratinocytes and an increased number of melanocytes. (See <a href=\"topic.htm?path=overview-of-benign-lesions-of-the-skin#H1101421989\" class=\"medical medical_review\">&quot;Overview of benign lesions of the skin&quot;, section on 'Seborrheic keratosis'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Lentigo maligna melanoma </strong>&ndash; Lentigo maligna melanoma results from the progression of LM to the invasive phase. Clinically, it presents as an hyperpigmented patch, with darker, asymmetric foci or nodules (<a href=\"image.htm?imageKey=DERM%2F74664%7EDERM%2F54753\" class=\"graphic graphic_picture graphicRef74664 graphicRef54753 \">picture 2C-D</a>). Histologically, neoplastic melanocytes are arrayed along the dermal-epidermal junction in a lentiginous pattern and form nests along the dermal-epidermal junction and nodules or fascicles in the dermis (<a href=\"image.htm?imageKey=ONC%2F73737\" class=\"graphic graphic_picture graphicRef73737 \">picture 7</a>). (See <a href=\"topic.htm?path=pathologic-characteristics-of-melanoma#H9\" class=\"medical medical_review\">&quot;Pathologic characteristics of melanoma&quot;, section on 'Lentigo maligna melanoma'</a>.)</p><p/><p class=\"headingAnchor\" id=\"H244299056\"><span class=\"h1\">TREATMENT</span></p><p class=\"headingAnchor\" id=\"H651881\"><span class=\"h2\">Overview</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>There are no randomized trials evaluating treatments for lentigo maligna (LM). However, surgical excision with 5 to 10 mm margins is recommended by multiple guidelines from several countries for all types of melanoma in situ, including LM [<a href=\"https://www.uptodate.com/contents/lentigo-maligna-clinical-manifestations-diagnosis-and-management/abstract/33-36\" class=\"abstract_t\">33-36</a>]. Surgical excision can include wide local excision, a staged procedure, or Mohs surgery. Wider margins may be needed for large lesions. (See <a href=\"#H651888\" class=\"local\">'Surgery'</a> below.)</p><p>Alternative treatments that have been used for LM include locally destructive therapies (radiation therapy, laser therapy, and cryotherapy,) and topical immunomodulator therapy with <a href=\"topic.htm?path=imiquimod-drug-information\" class=\"drug drug_general\">imiquimod</a>. Nonsurgical therapies, such as radiotherapy, may be appropriate in older patients with large lesions of the face that cannot be resected with adequate margins or when reconstruction is problematic. (See <a href=\"#H244299072\" class=\"local\">'Radiation therapy'</a> below.)</p><p class=\"headingAnchor\" id=\"H651888\"><span class=\"h2\">Surgery</span></p><p class=\"headingAnchor\" id=\"H244299065\"><span class=\"h3\">Wide local excision</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>There are no clinical trials evaluating the optimal excision margins for LM. Guidelines from the United Kingdom and from Australia recommend wide local excision (WLE) with 5 mm margins for all types of melanoma in situ, including LM, based upon 1992 recommendations of the National Institutes of Health (NIH) Consensus Panel on diagnosis and treatment of early melanoma [<a href=\"https://www.uptodate.com/contents/lentigo-maligna-clinical-manifestations-diagnosis-and-management/abstract/33,35,37\" class=\"abstract_t\">33,35,37</a>]. Guidelines from the American Academy of Dermatology, as well as the National Comprehensive Cancer Network Guidelines, state that LM may require excision margins &gt;5 mm to achieve histologically negative margins [<a href=\"https://www.uptodate.com/contents/lentigo-maligna-clinical-manifestations-diagnosis-and-management/abstract/34,36\" class=\"abstract_t\">34,36</a>]. </p><p>Multiple studies using surgical techniques that allow a complete margin examination (eg, staged excision or Mohs surgery) suggest that clearance rates with 5 or 6 mm margin range from 24 to 84 percent [<a href=\"https://www.uptodate.com/contents/lentigo-maligna-clinical-manifestations-diagnosis-and-management/abstract/16,38-41\" class=\"abstract_t\">16,38-41</a>]. Margins of 7 to 15 mm may be required to achieve clearance rates of 94 to 99 percent. A prospective study of 1072 patients with 1120 melanomas in situ treated by Mohs micrographic surgery found that a 9 mm margin was adequate for complete clearance in 98.9 percent of all tumors [<a href=\"https://www.uptodate.com/contents/lentigo-maligna-clinical-manifestations-diagnosis-and-management/abstract/42\" class=\"abstract_t\">42</a>]. Larger margins of 12 or 15 mm only marginally increased the clearance rate to 99.4 and 99.6 percent, respectively.</p><p>A few small studies have reported recurrence rates for conventional surgical excision of 6 to 9 percent after a mean follow-up time of 3 to 3.5 years [<a href=\"https://www.uptodate.com/contents/lentigo-maligna-clinical-manifestations-diagnosis-and-management/abstract/43,44\" class=\"abstract_t\">43,44</a>]. One study using staged excision for 55 LMs found that margins of 6 to 9 mm provided complete excision of lesions &lt;2 cm diameter (&lt;3 cm<sup>2</sup>), whereas margins of 8 to 12 mm cleared 95 percent of lesions &gt;2 cm [<a href=\"https://www.uptodate.com/contents/lentigo-maligna-clinical-manifestations-diagnosis-and-management/abstract/45\" class=\"abstract_t\">45</a>]. </p><p class=\"headingAnchor\" id=\"H190891\"><span class=\"h3\">Staged excision</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Staged excision with rush permanent sections (also called &quot;slow Mohs&quot;) is considered the optimal surgical technique for LM. Staged excision permits the evaluation of the surgical margins in a comprehensive manner similar to Mohs surgery, but relies on permanent sections rather than frozen sections. Permanent sections require a longer processing time than frozen sections; however, rush readings can usually be obtained in less than 24 hours.</p><p>After delineating the LM clinical margins, a surgical margin of 5 mm is drawn around the lesion (<a href=\"image.htm?imageKey=DERM%2F71333\" class=\"graphic graphic_figure graphicRef71333 \">figure 1</a>). The gross clinical lesion (&quot;tumor debulk&quot;) is excised down to the underlying adipose tissue, oriented, and placed in a formalin bottle. The margins are then excised to the underlying subcutaneous adipose tissue, divided, marked to preserve orientation, and placed in individually labeled formalin bottles. The tumor debulk tissue is serially sectioned in various ways (multiple vertical &quot;bread loaf&quot; sections or radial sections) and examined for invasive melanoma [<a href=\"https://www.uptodate.com/contents/lentigo-maligna-clinical-manifestations-diagnosis-and-management/abstract/45-49\" class=\"abstract_t\">45-49</a>]. The peripheral margins are inked with the same color consistently applied to the outer surface (true outer surgical margin). Each segment of the peripheral margin is sectioned vertically &quot;en face&quot; to allow the examination of the entire true margin. The permanent sections are evaluated by a dermatopathologist experienced in pigmented lesions. The margin status and location of residual melanoma is then communicated to the surgeon. The patient returns 24 hours later for reexcision of involved margins and the process is repeated until negative peripheral margins are achieved. Reconstruction of the defect is then performed.</p><p>There are several variations of the staged excision, including the &quot;square procedure,&quot; perimeter, contoured, and spaghetti techniques [<a href=\"https://www.uptodate.com/contents/lentigo-maligna-clinical-manifestations-diagnosis-and-management/abstract/50-54\" class=\"abstract_t\">50-54</a>]. In some of these techniques the margin specimens are cut en face in vertical sections that contain 100 percent of the peripheral margins. </p><p>Recurrence rates of 0 to 5 percent have been reported after staged excision at a mean follow-up time of 23 to 57 months [<a href=\"https://www.uptodate.com/contents/lentigo-maligna-clinical-manifestations-diagnosis-and-management/abstract/15,45-48,53,55\" class=\"abstract_t\">15,45-48,53,55</a>].</p><p class=\"headingAnchor\" id=\"H190898\"><span class=\"h3\">Mohs micrographic surgery</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Mohs micrographic surgery (MMS) is a technique that involves a beveled excision of the tumor. MMS uses frozen horizontal sections that allow for examination of the entire peripheral and deep margins of the tumor with maximal preservation of uninvolved tissue. (See <a href=\"topic.htm?path=mohs-surgery\" class=\"medical medical_review\">&quot;Mohs surgery&quot;</a>.)</p><p>However, the diagnosis of melanocytic lesions using frozen sections may be problematic. Differentiating atypical melanocytic hyperplasia from benign melanocytic hyperplasia and actinic keratinocytic damage is difficult and requires considerable experience in MMS and high quality frozen sections [<a href=\"https://www.uptodate.com/contents/lentigo-maligna-clinical-manifestations-diagnosis-and-management/abstract/56\" class=\"abstract_t\">56</a>]. Rapid immunostaining with MART-1 or Mel-5 may help in identifying the melanocytes on frozen sections and appears to provide information similar to that obtained from permanent sections [<a href=\"https://www.uptodate.com/contents/lentigo-maligna-clinical-manifestations-diagnosis-and-management/abstract/57-59\" class=\"abstract_t\">57-59</a>]. </p><p>Some Mohs surgeons, after a final negative frozen layer, excise an additional margin of 1 to 3 mm and send it for permanent sections. Some also send the central debulking specimen for permanent vertical sections for a more accurate staging of the tumor. </p><p>In one study including 116 patients with LM, 5 percent of margins that were negative on frozen sections were positive on permanent sections [<a href=\"https://www.uptodate.com/contents/lentigo-maligna-clinical-manifestations-diagnosis-and-management/abstract/60\" class=\"abstract_t\">60</a>]. In a review of 173 cases with an initial diagnosis of lentigo maligna or melanoma in situ and treated with MMS, the examination of permanent sections of the central debulking specimens led to an upstaging of the tumor in 14 (8 percent) of cases [<a href=\"https://www.uptodate.com/contents/lentigo-maligna-clinical-manifestations-diagnosis-and-management/abstract/61\" class=\"abstract_t\">61</a>]. In another review of LM and LMM cases treated with a staged excision technique with rush paraffin-embedded sections, 15 of 91 cases (16 percent) that were initially diagnosed as LM were found to be invasive melanomas [<a href=\"https://www.uptodate.com/contents/lentigo-maligna-clinical-manifestations-diagnosis-and-management/abstract/16\" class=\"abstract_t\">16</a>].</p><p>The recurrence rates for LM excised by MMS range from 0 to 2 percent after a follow-up time of 29 to 38 months [<a href=\"https://www.uptodate.com/contents/lentigo-maligna-clinical-manifestations-diagnosis-and-management/abstract/57,62-64\" class=\"abstract_t\">57,62-64</a>]. </p><p class=\"headingAnchor\" id=\"H652399\"><span class=\"h2\">Nonsurgical therapies</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Nonsurgical therapy for LM should only be considered under select clinical circumstances, when surgical excision is not feasible [<a href=\"https://www.uptodate.com/contents/lentigo-maligna-clinical-manifestations-diagnosis-and-management/abstract/34\" class=\"abstract_t\">34</a>]. Alternatives to surgery include radiotherapy, topical <a href=\"topic.htm?path=imiquimod-drug-information\" class=\"drug drug_general\">imiquimod</a>, cryosurgery, and laser therapy. These techniques have not been evaluated in randomized trials. </p><p>One study reviewed 1086 cases of melanoma in situ treated with surgery or nonsurgical interventions. The proportion of these that were LM was not specified; 721 cases involved the head or neck. The five-year recurrence rate was 6.8 percent for surgical excision and 31 percent for radiotherapy, laser therapy, and cryosurgery combined as a single category [<a href=\"https://www.uptodate.com/contents/lentigo-maligna-clinical-manifestations-diagnosis-and-management/abstract/65\" class=\"abstract_t\">65</a>]. In a small retrospective study of 73 patients, carbon dioxide laser treatment was used in 15 patients refusing surgery and radiotherapy, with one recurrence (6.7 percent) after a median follow-up time of 78 months [<a href=\"https://www.uptodate.com/contents/lentigo-maligna-clinical-manifestations-diagnosis-and-management/abstract/66\" class=\"abstract_t\">66</a>].</p><p>Drawbacks of nonsurgical therapy include:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Lack of histologic examination of the entire tumor for foci of dermal invasion not evident at the initial biopsy </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Lack of histologic margin control </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Post-treatment monitoring based upon clinical examination or random biopsies that may not show tumor persistence or recurrence </p><p/><p class=\"headingAnchor\" id=\"H244299072\"><span class=\"h3\">Radiation therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Radiation therapy (XRT) is a treatment option for large LM lesions in older patients for whom surgical removal would not be feasible. (See <a href=\"topic.htm?path=radiation-therapy-in-the-management-of-melanoma#H8198913\" class=\"medical medical_review\">&quot;Radiation therapy in the management of melanoma&quot;, section on 'Cutaneous primary lesions'</a>.)</p><p>Multifractionated regimens of high voltage (100 kV to 280 kV) delivered at depths of 5 to 6 mm with minimum margins of 7 to 10 mm have been used in small series of patients in the United States and Canada [<a href=\"https://www.uptodate.com/contents/lentigo-maligna-clinical-manifestations-diagnosis-and-management/abstract/43,67\" class=\"abstract_t\">43,67</a>]. In one study, the cure rate at 5 years was 86 percent [<a href=\"https://www.uptodate.com/contents/lentigo-maligna-clinical-manifestations-diagnosis-and-management/abstract/43\" class=\"abstract_t\">43</a>]. In Europe, low energy grenz rays (12 kV) or soft x-rays (20-50 kV) delivered at a depth of about 1 mm are used. </p><p>Recurrence rates of 0 and 5 percent have been reported in small studies after a follow-up time of one to 108 months [<a href=\"https://www.uptodate.com/contents/lentigo-maligna-clinical-manifestations-diagnosis-and-management/abstract/5,68\" class=\"abstract_t\">5,68</a>]. In a large series of 350 patients with LMs and early lentigo maligna melanoma (LMM) treated with grenz rays as primary therapy, the clearance rate was 83 percent after a median follow-up time of about 5 years [<a href=\"https://www.uptodate.com/contents/lentigo-maligna-clinical-manifestations-diagnosis-and-management/abstract/69\" class=\"abstract_t\">69</a>]. In a review of eight retrospective, single institution studies including 349 patients with LM, the overall recurrence rate was 5 percent after a median follow-up of three years [<a href=\"https://www.uptodate.com/contents/lentigo-maligna-clinical-manifestations-diagnosis-and-management/abstract/70\" class=\"abstract_t\">70</a>]. Progression to LMM occurred in 1.4 percent of patients. </p><p class=\"headingAnchor\" id=\"H244299079\"><span class=\"h3\">Topical imiquimod</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=imiquimod-drug-information\" class=\"drug drug_general\">Imiquimod</a> 5% cream is approved by the US Food and Drug Administration for the treatment of actinic keratoses, superficial basal cell carcinomas, and warts. Several reports of its use &quot;off-label&quot; for LM show some apparent response to topical imiquimod. The mechanism of action proposed is that imiquimod induces a local inflammatory response of T-helper lymphocytes mixed with cytotoxic cells, monocytes, and macrophages, leading to a cytotoxic T-cell mediated immune response [<a href=\"https://www.uptodate.com/contents/lentigo-maligna-clinical-manifestations-diagnosis-and-management/abstract/71\" class=\"abstract_t\">71</a>]. </p><p>In a few small studies, the response rates by visual inspection to topical <a href=\"topic.htm?path=imiquimod-drug-information\" class=\"drug drug_general\">imiquimod</a> were 56 to 93 percent after a follow-up of 12 to 49 months [<a href=\"https://www.uptodate.com/contents/lentigo-maligna-clinical-manifestations-diagnosis-and-management/abstract/72-75\" class=\"abstract_t\">72-75</a>]. However, histologic verification after treatment showed persistent disease in 25 to 47 percent of treated patients [<a href=\"https://www.uptodate.com/contents/lentigo-maligna-clinical-manifestations-diagnosis-and-management/abstract/76-78\" class=\"abstract_t\">76-78</a>]. Recurrences with development of LMM were reported in all case series. </p><p class=\"headingAnchor\" id=\"H244299100\"><span class=\"h1\">PROGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Lentigo maligna (LM) has a tendency for subclinical spread. Atypical melanocytes often extend for a considerable distance from the clinical margin of LM, sometimes involving &quot;skip&quot; areas. This phenomenon is described as the &quot;field effect&quot; and is responsible for recurrence of LM at the edge after an initial apparently successful treatment.</p><p>Recurrence may occur after a prolonged disease-free interval, making assessment of the efficacy of therapy difficult in studies with follow-up time &le;5 years. However, in the absence of progression to lentigo maligna melanoma, LM does not shorten life expectancy. </p><p class=\"headingAnchor\" id=\"H244299107\"><span class=\"h1\">FOLLOW-UP</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>There is no evidence base to determine the optimal follow-up for patients with lentigo maligna (LM). Following excision of LM, most clinicians see patients twice a year for the first five years, and annually thereafter. </p><p>Examination for recurrent lesions or new primary lesions is enhanced by the use of dermoscopy or by examination in a darkened room using a Wood's light. </p><p>Since LM typically occurs in patients with substantially sun-damaged skin who are at increased risk of melanoma and nonmelanoma skin cancer, full-body skin examination should be performed in these patients at each follow-up visit. </p><p class=\"headingAnchor\" id=\"H652546\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Lentigo maligna is a slowly evolving type of melanoma in situ that typically occurs in the sun-damaged skin of the face and neck of older individuals (<a href=\"image.htm?imageKey=DERM%2F62052%7EDERM%2F59591%7EDERM%2F68787%7EDERM%2F75238%7EDERM%2F77206\" class=\"graphic graphic_picture graphicRef62052 graphicRef59591 graphicRef68787 graphicRef75238 graphicRef77206 \">picture 1A-E</a>). The risk of progression to invasive lentigo maligna melanoma ranges from 5 to 20 percent. The development of darker pigmentation, sharper borders, or elevated or nodular areas are clinical signs of progression. (See <a href=\"#H244299028\" class=\"local\">'Epidemiology and natural history'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Clinically, lentigo maligna presents as an atypical macular lesion characterized by irregular shape, variegated color, and variable size (<a href=\"image.htm?imageKey=DERM%2F62052%7EDERM%2F59591%7EDERM%2F68787%7EDERM%2F75238%7EDERM%2F77206\" class=\"graphic graphic_picture graphicRef62052 graphicRef59591 graphicRef68787 graphicRef75238 graphicRef77206 \">picture 1A-E</a>). Dermoscopic features of lentigo maligna include asymmetrical pigmented follicular openings, dark rhomboidal structures, and slate-gray dots and globules (<a href=\"image.htm?imageKey=DERM%2F68828\" class=\"graphic graphic_picture graphicRef68828 \">picture 3B</a>). The surrounding skin typically shows evidence of chronic solar damage (solar elastosis, solar lentigines, or actinic keratoses). (See <a href=\"#H244299035\" class=\"local\">'Clinical features'</a> above and <a href=\"#H2436682\" class=\"local\">'Dermoscopic features'</a> above.) </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The diagnosis of lentigo maligna is made by histologic examination. Excisional biopsy with narrow margins is ideal for diagnosis. For large lesions or lesions located in cosmetically sensitive areas, it is acceptable to perform one or more incisional biopsies of the most irregular or heavily pigmented areas. Dermoscopy may be helpful in the selection of the biopsy site. Histologically, lentigo maligna is characterized by the replacement of basal keratinocytes by atypical melanocytes without dermal invasion. (See <a href=\"#H20157199\" class=\"local\">'Diagnosis'</a> above and <a href=\"#H244299042\" class=\"local\">'Histopathologic features'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>There are no randomized trials evaluating treatment for lentigo maligna. We suggest surgical excision with margins of 5 to 10 mm, depending upon lesion size and location (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>). If available, surgical techniques that allow complete margin control such as staged excision with permanent sections (&quot;slow&quot; Mohs) are a preferred option. (See <a href=\"#H244299065\" class=\"local\">'Wide local excision'</a> above and <a href=\"#H190891\" class=\"local\">'Staged excision'</a> above and <a href=\"#H190898\" class=\"local\">'Mohs micrographic surgery'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Among nonsurgical treatments for lentigo maligna, options include radiation therapy with multifractionated high voltage regimens or grenz rays or soft x-rays for large lesions in older patients for whom surgical removal and reconstruction would be difficult. (See <a href=\"#H244299072\" class=\"local\">'Radiation therapy'</a> above.)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li class=\"breakAll\">World Health Organization Classification of Tumors. Pathology &amp; Genetics. Skin Tumors. Chapter 2. Melanocytic Tumors. http://www.iarc.fr/en/publications/pdfs-online/pat-gen/bb6/bb6-chap2.pdf (Accessed on November 29, 2011).</li><li><a href=\"https://www.uptodate.com/contents/lentigo-maligna-clinical-manifestations-diagnosis-and-management/abstract/2\" class=\"nounderline abstract_t\">Hutchinson J. Notes on the cancerous process and on new growths in general. Arch Surg (London) 1890; 2:83.</a></li><li><a href=\"https://www.uptodate.com/contents/lentigo-maligna-clinical-manifestations-diagnosis-and-management/abstract/3\" class=\"nounderline abstract_t\">Dubreuilh MW. De la melanose circonscrite precancereuse. Ann Dermatol Syphil 1912; 3:129, 205.</a></li><li><a href=\"https://www.uptodate.com/contents/lentigo-maligna-clinical-manifestations-diagnosis-and-management/abstract/4\" class=\"nounderline abstract_t\">Cohen LM. Lentigo maligna and lentigo maligna melanoma. J Am Acad Dermatol 1995; 33:923.</a></li><li><a href=\"https://www.uptodate.com/contents/lentigo-maligna-clinical-manifestations-diagnosis-and-management/abstract/5\" class=\"nounderline abstract_t\">Farshad A, Burg G, Panizzon R, Dummer R. A retrospective study of 150 patients with lentigo maligna and lentigo maligna melanoma and the efficacy of radiotherapy using Grenz or soft X-rays. Br J Dermatol 2002; 146:1042.</a></li><li><a href=\"https://www.uptodate.com/contents/lentigo-maligna-clinical-manifestations-diagnosis-and-management/abstract/6\" class=\"nounderline abstract_t\">Swetter SM, Boldrick JC, Jung SY, et al. Increasing incidence of lentigo maligna melanoma subtypes: northern California and national trends 1990-2000. J Invest Dermatol 2005; 125:685.</a></li><li><a href=\"https://www.uptodate.com/contents/lentigo-maligna-clinical-manifestations-diagnosis-and-management/abstract/7\" class=\"nounderline abstract_t\">Mirzoyev SA, Knudson RM, Reed KB, et al. Incidence of lentigo maligna in Olmsted County, Minnesota, 1970 to 2007. J Am Acad Dermatol 2014; 70:443.</a></li><li><a href=\"https://www.uptodate.com/contents/lentigo-maligna-clinical-manifestations-diagnosis-and-management/abstract/8\" class=\"nounderline abstract_t\">Kvaskoff M, Siskind V, Green AC. Risk factors for lentigo maligna melanoma compared with superficial spreading melanoma: a case-control study in Australia. Arch Dermatol 2012; 148:164.</a></li><li><a href=\"https://www.uptodate.com/contents/lentigo-maligna-clinical-manifestations-diagnosis-and-management/abstract/9\" class=\"nounderline abstract_t\">Gaudy-Marqueste C, Madjlessi N, Guillot B, et al. Risk factors in elderly people for lentigo maligna compared with other melanomas: a double case-control study. Arch Dermatol 2009; 145:418.</a></li><li><a href=\"https://www.uptodate.com/contents/lentigo-maligna-clinical-manifestations-diagnosis-and-management/abstract/10\" class=\"nounderline abstract_t\">Jackson R, Williamson GS, Beattie WG. Lentigo maligna and malignant melanoma. Can Med Assoc J 1966; 95:846.</a></li><li><a href=\"https://www.uptodate.com/contents/lentigo-maligna-clinical-manifestations-diagnosis-and-management/abstract/11\" class=\"nounderline abstract_t\">Grinspan D, Paz A, Abulafia J, Mosto S. [Melanoma (Hutchinson's lentigo maligna) having spontaneous regression. A case of immunologic importance]. Med Cutan Ibero Lat Am 1980; 8:33.</a></li><li><a href=\"https://www.uptodate.com/contents/lentigo-maligna-clinical-manifestations-diagnosis-and-management/abstract/12\" class=\"nounderline abstract_t\">Clark WH Jr, Mihm MC Jr. Lentigo maligna and lentigo-maligna melanoma. Am J Pathol 1969; 55:39.</a></li><li><a href=\"https://www.uptodate.com/contents/lentigo-maligna-clinical-manifestations-diagnosis-and-management/abstract/13\" class=\"nounderline abstract_t\">Weinstock MA, Sober AJ. The risk of progression of lentigo maligna to lentigo maligna melanoma. Br J Dermatol 1987; 116:303.</a></li><li><a href=\"https://www.uptodate.com/contents/lentigo-maligna-clinical-manifestations-diagnosis-and-management/abstract/14\" class=\"nounderline abstract_t\">Penneys NS. Microinvasive lentigo maligna melanoma. J Am Acad Dermatol 1987; 17:675.</a></li><li><a href=\"https://www.uptodate.com/contents/lentigo-maligna-clinical-manifestations-diagnosis-and-management/abstract/15\" class=\"nounderline abstract_t\">Bosbous MW, Dzwierzynski WW, Neuburg M. Staged excision of lentigo maligna and lentigo maligna melanoma: a 10-year experience. Plast Reconstr Surg 2009; 124:1947.</a></li><li><a href=\"https://www.uptodate.com/contents/lentigo-maligna-clinical-manifestations-diagnosis-and-management/abstract/16\" class=\"nounderline abstract_t\">Hazan C, Dusza SW, Delgado R, et al. Staged excision for lentigo maligna and lentigo maligna melanoma: A retrospective analysis of 117 cases. J Am Acad Dermatol 2008; 58:142.</a></li><li><a href=\"https://www.uptodate.com/contents/lentigo-maligna-clinical-manifestations-diagnosis-and-management/abstract/17\" class=\"nounderline abstract_t\">Somach SC, Taira JW, Pitha JV, Everett MA. Pigmented lesions in actinically damaged skin. Histopathologic comparison of biopsy and excisional specimens. Arch Dermatol 1996; 132:1297.</a></li><li><a href=\"https://www.uptodate.com/contents/lentigo-maligna-clinical-manifestations-diagnosis-and-management/abstract/18\" class=\"nounderline abstract_t\">Burket JM. Amelanotic lentigo maligna. Arch Dermatol 1979; 115:496.</a></li><li><a href=\"https://www.uptodate.com/contents/lentigo-maligna-clinical-manifestations-diagnosis-and-management/abstract/19\" class=\"nounderline abstract_t\">Su WP, Bradley RR. Amelanotic lentigo maligna. Arch Dermatol 1980; 116:82.</a></li><li><a href=\"https://www.uptodate.com/contents/lentigo-maligna-clinical-manifestations-diagnosis-and-management/abstract/20\" class=\"nounderline abstract_t\">Argenziano G, Soyer HP, Chimenti S, et al. Dermoscopy of pigmented skin lesions: results of a consensus meeting via the Internet. J Am Acad Dermatol 2003; 48:679.</a></li><li><a href=\"https://www.uptodate.com/contents/lentigo-maligna-clinical-manifestations-diagnosis-and-management/abstract/21\" class=\"nounderline abstract_t\">Stolz W, Schiffner R, Burgdorf WH. Dermatoscopy for facial pigmented skin lesions. Clin Dermatol 2002; 20:276.</a></li><li><a href=\"https://www.uptodate.com/contents/lentigo-maligna-clinical-manifestations-diagnosis-and-management/abstract/22\" class=\"nounderline abstract_t\">Akay BN, Kocyigit P, Heper AO, Erdem C. Dermatoscopy of flat pigmented facial lesions: diagnostic challenge between pigmented actinic keratosis and lentigo maligna. Br J Dermatol 2010; 163:1212.</a></li><li><a href=\"https://www.uptodate.com/contents/lentigo-maligna-clinical-manifestations-diagnosis-and-management/abstract/23\" class=\"nounderline abstract_t\">Zalaudek I, Ferrara G, Leinweber B, et al. Pitfalls in the clinical and dermoscopic diagnosis of pigmented actinic keratosis. J Am Acad Dermatol 2005; 53:1071.</a></li><li><a href=\"https://www.uptodate.com/contents/lentigo-maligna-clinical-manifestations-diagnosis-and-management/abstract/24\" class=\"nounderline abstract_t\">Schiffner R, Schiffner-Rohe J, Vogt T, et al. Improvement of early recognition of lentigo maligna using dermatoscopy. J Am Acad Dermatol 2000; 42:25.</a></li><li><a href=\"https://www.uptodate.com/contents/lentigo-maligna-clinical-manifestations-diagnosis-and-management/abstract/25\" class=\"nounderline abstract_t\">Tiodorovic-Zivkovic D, Argenziano G, Lallas A, et al. Age, gender, and topography influence the clinical and dermoscopic appearance of lentigo maligna. J Am Acad Dermatol 2015; 72:801.</a></li><li><a href=\"https://www.uptodate.com/contents/lentigo-maligna-clinical-manifestations-diagnosis-and-management/abstract/26\" class=\"nounderline abstract_t\">Weyers W, Bonczkowitz M, Weyers I, et al. Melanoma in situ versus melanocytic hyperplasia in sun-damaged skin. Assessment of the significance of histopathologic criteria for differential diagnosis. Am J Dermatopathol 1996; 18:560.</a></li><li><a href=\"https://www.uptodate.com/contents/lentigo-maligna-clinical-manifestations-diagnosis-and-management/abstract/27\" class=\"nounderline abstract_t\">Trotter MJ. Melanoma margin assessment. Clin Lab Med 2011; 31:289.</a></li><li><a href=\"https://www.uptodate.com/contents/lentigo-maligna-clinical-manifestations-diagnosis-and-management/abstract/28\" class=\"nounderline abstract_t\">Flotte TJ, Mihm MC Jr. Lentigo maligna and malignant melanoma in situ, lentigo maligna type. Hum Pathol 1999; 30:533.</a></li><li><a href=\"https://www.uptodate.com/contents/lentigo-maligna-clinical-manifestations-diagnosis-and-management/abstract/29\" class=\"nounderline abstract_t\">Langley RG, Burton E, Walsh N, et al. In vivo confocal scanning laser microscopy of benign lentigines: comparison to conventional histology and in vivo characteristics of lentigo maligna. J Am Acad Dermatol 2006; 55:88.</a></li><li><a href=\"https://www.uptodate.com/contents/lentigo-maligna-clinical-manifestations-diagnosis-and-management/abstract/30\" class=\"nounderline abstract_t\">Ahlgrimm-Siess V, Massone C, Scope A, et al. Reflectance confocal microscopy of facial lentigo maligna and lentigo maligna melanoma: a preliminary study. Br J Dermatol 2009; 161:1307.</a></li><li><a href=\"https://www.uptodate.com/contents/lentigo-maligna-clinical-manifestations-diagnosis-and-management/abstract/31\" class=\"nounderline abstract_t\">Wurm EM, Curchin CE, Lambie D, et al. Confocal features of equivocal facial lesions on severely sun-damaged skin: four case studies with dermatoscopic, confocal, and histopathologic correlation. J Am Acad Dermatol 2012; 66:463.</a></li><li><a href=\"https://www.uptodate.com/contents/lentigo-maligna-clinical-manifestations-diagnosis-and-management/abstract/32\" class=\"nounderline abstract_t\">Guitera P, Pellacani G, Crotty KA, et al. The impact of in vivo reflectance confocal microscopy on the diagnostic accuracy of lentigo maligna and equivocal pigmented and nonpigmented macules of the face. J Invest Dermatol 2010; 130:2080.</a></li><li><a href=\"https://www.uptodate.com/contents/lentigo-maligna-clinical-manifestations-diagnosis-and-management/abstract/33\" class=\"nounderline abstract_t\">Marsden JR, Newton-Bishop JA, Burrows L, et al. Revised U.K. guidelines for the management of cutaneous melanoma 2010. Br J Dermatol 2010; 163:238.</a></li><li><a href=\"https://www.uptodate.com/contents/lentigo-maligna-clinical-manifestations-diagnosis-and-management/abstract/34\" class=\"nounderline abstract_t\">Bichakjian CK, Halpern AC, Johnson TM, et al. Guidelines of care for the management of primary cutaneous melanoma. American Academy of Dermatology. J Am Acad Dermatol 2011; 65:1032.</a></li><li class=\"breakAll\">Australian Cancer Network Melanoma Guidelines Revision Working Party. Clinical Practice Guidelines\r\nfor the Management of Melanoma in Australia and New Zealand. Cancer Council Australia and\r\nAustralian Cancer Network, Sydney and New Zealand Guidelines Group, Wellington (2008). http://www.health.govt.nz/system/files/documents/publications/melanoma-guideline-nov08-v2.pdf (Accessed on November 29, 2011).</li><li class=\"breakAll\">National Comprhensive Cancer Network Clinical Practice Guidelines in Oncology. Melanoma. Version 3.2012. http://www.nccn.org/professionals/physician_gls/pdf/melanoma.pdf (Accessed on December 09, 2011).</li><li><a href=\"https://www.uptodate.com/contents/lentigo-maligna-clinical-manifestations-diagnosis-and-management/abstract/37\" class=\"nounderline abstract_t\">NIH Consensus conference. Diagnosis and treatment of early melanoma. JAMA 1992; 268:1314.</a></li><li><a href=\"https://www.uptodate.com/contents/lentigo-maligna-clinical-manifestations-diagnosis-and-management/abstract/38\" class=\"nounderline abstract_t\">Huilgol SC, Selva D, Chen C, et al. Surgical margins for lentigo maligna and lentigo maligna melanoma: the technique of mapped serial excision. Arch Dermatol 2004; 140:1087.</a></li><li><a href=\"https://www.uptodate.com/contents/lentigo-maligna-clinical-manifestations-diagnosis-and-management/abstract/39\" class=\"nounderline abstract_t\">Albertini JG, Elston DM, Libow LF, et al. Mohs micrographic surgery for melanoma: a case series, a comparative study of immunostains, an informative case report, and a unique mapping technique. Dermatol Surg 2002; 28:656.</a></li><li><a href=\"https://www.uptodate.com/contents/lentigo-maligna-clinical-manifestations-diagnosis-and-management/abstract/40\" class=\"nounderline abstract_t\">Zalla MJ, Lim KK, Dicaudo DJ, Gagnot MM. Mohs micrographic excision of melanoma using immunostains. Dermatol Surg 2000; 26:771.</a></li><li><a href=\"https://www.uptodate.com/contents/lentigo-maligna-clinical-manifestations-diagnosis-and-management/abstract/41\" class=\"nounderline abstract_t\">Bricca GM, Brodland DG, Ren D, Zitelli JA. Cutaneous head and neck melanoma treated with Mohs micrographic surgery. J Am Acad Dermatol 2005; 52:92.</a></li><li><a href=\"https://www.uptodate.com/contents/lentigo-maligna-clinical-manifestations-diagnosis-and-management/abstract/42\" class=\"nounderline abstract_t\">Kunishige JH, Brodland DG, Zitelli JA. Surgical margins for melanoma in situ. J Am Acad Dermatol 2012; 66:438.</a></li><li><a href=\"https://www.uptodate.com/contents/lentigo-maligna-clinical-manifestations-diagnosis-and-management/abstract/43\" class=\"nounderline abstract_t\">Tsang RW, Liu FF, Wells W, Payne DG. Lentigo maligna of the head and neck. Results of treatment by radiotherapy. Arch Dermatol 1994; 130:1008.</a></li><li><a href=\"https://www.uptodate.com/contents/lentigo-maligna-clinical-manifestations-diagnosis-and-management/abstract/44\" class=\"nounderline abstract_t\">Coleman WP 3rd, Davis RS, Reed RJ, Krementz ET. Treatment of lentigo maligna and lentigo maligna melanoma. J Dermatol Surg Oncol 1980; 6:476.</a></li><li><a href=\"https://www.uptodate.com/contents/lentigo-maligna-clinical-manifestations-diagnosis-and-management/abstract/45\" class=\"nounderline abstract_t\">Bub JL, Berg D, Slee A, Odland PB. Management of lentigo maligna and lentigo maligna melanoma with staged excision: a 5-year follow-up. Arch Dermatol 2004; 140:552.</a></li><li><a href=\"https://www.uptodate.com/contents/lentigo-maligna-clinical-manifestations-diagnosis-and-management/abstract/46\" class=\"nounderline abstract_t\">Agarwal-Antal N, Bowen GM, Gerwels JW. Histologic evaluation of lentigo maligna with permanent sections: implications regarding current guidelines. J Am Acad Dermatol 2002; 47:743.</a></li><li><a href=\"https://www.uptodate.com/contents/lentigo-maligna-clinical-manifestations-diagnosis-and-management/abstract/47\" class=\"nounderline abstract_t\">Hill DC, Gramp AA. Surgical treatment of lentigo maligna and lentigo maligna melanoma. Australas J Dermatol 1999; 40:25.</a></li><li><a href=\"https://www.uptodate.com/contents/lentigo-maligna-clinical-manifestations-diagnosis-and-management/abstract/48\" class=\"nounderline abstract_t\">Malhotra R, Chen C, Huilgol SC, et al. Mapped serial excision for periocular lentigo maligna and lentigo maligna melanoma. Ophthalmology 2003; 110:2011.</a></li><li><a href=\"https://www.uptodate.com/contents/lentigo-maligna-clinical-manifestations-diagnosis-and-management/abstract/49\" class=\"nounderline abstract_t\">McGuire LK, Disa JJ, Lee EH, et al. Melanoma of the lentigo maligna subtype: diagnostic challenges and current treatment paradigms. Plast Reconstr Surg 2012; 129:288e.</a></li><li><a href=\"https://www.uptodate.com/contents/lentigo-maligna-clinical-manifestations-diagnosis-and-management/abstract/50\" class=\"nounderline abstract_t\">Johnson TM, Headington JT, Baker SR, Lowe L. Usefulness of the staged excision for lentigo maligna and lentigo maligna melanoma: the &quot;square&quot; procedure. J Am Acad Dermatol 1997; 37:758.</a></li><li><a href=\"https://www.uptodate.com/contents/lentigo-maligna-clinical-manifestations-diagnosis-and-management/abstract/51\" class=\"nounderline abstract_t\">Anderson KW, Baker SR, Lowe L, et al. Treatment of head and neck melanoma, lentigo maligna subtype: a practical surgical technique. Arch Facial Plast Surg 2001; 3:202.</a></li><li><a href=\"https://www.uptodate.com/contents/lentigo-maligna-clinical-manifestations-diagnosis-and-management/abstract/52\" class=\"nounderline abstract_t\">Gaudy-Marqueste C, Perchenet AS, Tas&eacute;i AM, et al. The &quot;spaghetti technique&quot;: an alternative to Mohs surgery or staged surgery for problematic lentiginous melanoma (lentigo maligna and acral lentiginous melanoma). J Am Acad Dermatol 2011; 64:113.</a></li><li><a href=\"https://www.uptodate.com/contents/lentigo-maligna-clinical-manifestations-diagnosis-and-management/abstract/53\" class=\"nounderline abstract_t\">M&ouml;ller MG, Pappas-Politis E, Zager JS, et al. Surgical management of melanoma-in-situ using a staged marginal and central excision technique. Ann Surg Oncol 2009; 16:1526.</a></li><li><a href=\"https://www.uptodate.com/contents/lentigo-maligna-clinical-manifestations-diagnosis-and-management/abstract/54\" class=\"nounderline abstract_t\">Mahoney MH, Joseph M, Temple CL. The perimeter technique for lentigo maligna: an alternative to Mohs micrographic surgery. J Surg Oncol 2005; 91:120.</a></li><li><a href=\"https://www.uptodate.com/contents/lentigo-maligna-clinical-manifestations-diagnosis-and-management/abstract/55\" class=\"nounderline abstract_t\">Demirci H, Johnson TM, Frueh BR, et al. Management of periocular cutaneous melanoma with a staged excision technique and permanent sections the square procedure. Ophthalmology 2008; 115:2295.</a></li><li><a href=\"https://www.uptodate.com/contents/lentigo-maligna-clinical-manifestations-diagnosis-and-management/abstract/56\" class=\"nounderline abstract_t\">Kwon SY, Miller SJ. Mohs surgery for melanoma in situ. Dermatol Clin 2011; 29:175.</a></li><li><a href=\"https://www.uptodate.com/contents/lentigo-maligna-clinical-manifestations-diagnosis-and-management/abstract/57\" class=\"nounderline abstract_t\">Bhardwaj SS, Tope WD, Lee PK. Mohs micrographic surgery for lentigo maligna and lentigo maligna melanoma using Mel-5 immunostaining: University of Minnesota experience. Dermatol Surg 2006; 32:690.</a></li><li><a href=\"https://www.uptodate.com/contents/lentigo-maligna-clinical-manifestations-diagnosis-and-management/abstract/58\" class=\"nounderline abstract_t\">Cherpelis BS, Moore R, Ladd S, et al. Comparison of MART-1 frozen sections to permanent sections using a rapid 19-minute protocol. Dermatol Surg 2009; 35:207.</a></li><li><a href=\"https://www.uptodate.com/contents/lentigo-maligna-clinical-manifestations-diagnosis-and-management/abstract/59\" class=\"nounderline abstract_t\">Bricca GM, Brodland DG, Zitelli JA. Immunostaining melanoma frozen sections: the 1-hour protocol. Dermatol Surg 2004; 30:403.</a></li><li><a href=\"https://www.uptodate.com/contents/lentigo-maligna-clinical-manifestations-diagnosis-and-management/abstract/60\" class=\"nounderline abstract_t\">Bene NI, Healy C, Coldiron BM. Mohs micrographic surgery is accurate 95.1% of the time for melanoma in situ: a prospective study of 167 cases. Dermatol Surg 2008; 34:660.</a></li><li><a href=\"https://www.uptodate.com/contents/lentigo-maligna-clinical-manifestations-diagnosis-and-management/abstract/61\" class=\"nounderline abstract_t\">Iorizzo LJ 3rd, Chocron I, Lumbang W, Stasko T. Importance of vertical pathology of debulking specimens during Mohs micrographic surgery for lentigo maligna and melanoma in situ. Dermatol Surg 2013; 39:365.</a></li><li><a href=\"https://www.uptodate.com/contents/lentigo-maligna-clinical-manifestations-diagnosis-and-management/abstract/62\" class=\"nounderline abstract_t\">Temple CL, Arlette JP. Mohs micrographic surgery in the treatment of lentigo maligna and melanoma. J Surg Oncol 2006; 94:287.</a></li><li><a href=\"https://www.uptodate.com/contents/lentigo-maligna-clinical-manifestations-diagnosis-and-management/abstract/63\" class=\"nounderline abstract_t\">Bienert TN, Trotter MJ, Arlette JP. Treatment of cutaneous melanoma of the face by Mohs micrographic surgery. J Cutan Med Surg 2003; 7:25.</a></li><li><a href=\"https://www.uptodate.com/contents/lentigo-maligna-clinical-manifestations-diagnosis-and-management/abstract/64\" class=\"nounderline abstract_t\">Dawn ME, Dawn AG, Miller SJ. Mohs surgery for the treatment of melanoma in situ: a review. Dermatol Surg 2007; 33:395.</a></li><li><a href=\"https://www.uptodate.com/contents/lentigo-maligna-clinical-manifestations-diagnosis-and-management/abstract/65\" class=\"nounderline abstract_t\">Zalaudek I, Horn M, Richtig E, et al. Local recurrence in melanoma in situ: influence of sex, age, site of involvement and therapeutic modalities. Br J Dermatol 2003; 148:703.</a></li><li><a href=\"https://www.uptodate.com/contents/lentigo-maligna-clinical-manifestations-diagnosis-and-management/abstract/66\" class=\"nounderline abstract_t\">Lee H, Sowerby LJ, Temple CL, et al. Carbon dioxide laser treatment for lentigo maligna: a retrospective review comparing 3 different treatment modalities. Arch Facial Plast Surg 2011; 13:398.</a></li><li><a href=\"https://www.uptodate.com/contents/lentigo-maligna-clinical-manifestations-diagnosis-and-management/abstract/67\" class=\"nounderline abstract_t\">Harwood AR. Conventional radiotherapy in the treatment of lentigo maligna and lentigo maligna melanoma. J Am Acad Dermatol 1982; 6:310.</a></li><li><a href=\"https://www.uptodate.com/contents/lentigo-maligna-clinical-manifestations-diagnosis-and-management/abstract/68\" class=\"nounderline abstract_t\">Schmid-Wendtner MH, Brunner B, Konz B, et al. Fractionated radiotherapy of lentigo maligna and lentigo maligna melanoma in 64 patients. J Am Acad Dermatol 2000; 43:477.</a></li><li><a href=\"https://www.uptodate.com/contents/lentigo-maligna-clinical-manifestations-diagnosis-and-management/abstract/69\" class=\"nounderline abstract_t\">Hedblad MA, Mallbris L. Grenz ray treatment of lentigo maligna and early lentigo maligna melanoma. J Am Acad Dermatol 2012; 67:60.</a></li><li><a href=\"https://www.uptodate.com/contents/lentigo-maligna-clinical-manifestations-diagnosis-and-management/abstract/70\" class=\"nounderline abstract_t\">Fogarty GB, Hong A, Scolyer RA, et al. Radiotherapy for lentigo maligna: a literature review and recommendations for treatment. Br J Dermatol 2014; 170:52.</a></li><li><a href=\"https://www.uptodate.com/contents/lentigo-maligna-clinical-manifestations-diagnosis-and-management/abstract/71\" class=\"nounderline abstract_t\">Wolf IH, Cerroni L, Kodama K, Kerl H. Treatment of lentigo maligna (melanoma in situ) with the immune response modifier imiquimod. Arch Dermatol 2005; 141:510.</a></li><li><a href=\"https://www.uptodate.com/contents/lentigo-maligna-clinical-manifestations-diagnosis-and-management/abstract/72\" class=\"nounderline abstract_t\">Rajpar SF, Marsden JR. Imiquimod in the treatment of lentigo maligna. Br J Dermatol 2006; 155:653.</a></li><li><a href=\"https://www.uptodate.com/contents/lentigo-maligna-clinical-manifestations-diagnosis-and-management/abstract/73\" class=\"nounderline abstract_t\">Buettiker UV, Yawalkar NY, Braathen LR, Hunger RE. Imiquimod treatment of lentigo maligna: an open-label study of 34 primary lesions in 32 patients. Arch Dermatol 2008; 144:943.</a></li><li><a href=\"https://www.uptodate.com/contents/lentigo-maligna-clinical-manifestations-diagnosis-and-management/abstract/74\" class=\"nounderline abstract_t\">Powell AM, Robson AM, Russell-Jones R, Barlow RJ. Imiquimod and lentigo maligna: a search for prognostic features in a clinicopathological study with long-term follow-up. Br J Dermatol 2009; 160:994.</a></li><li><a href=\"https://www.uptodate.com/contents/lentigo-maligna-clinical-manifestations-diagnosis-and-management/abstract/75\" class=\"nounderline abstract_t\">Naylor MF, Crowson N, Kuwahara R, et al. Treatment of lentigo maligna with topical imiquimod. Br J Dermatol 2003; 149 Suppl 66:66.</a></li><li><a href=\"https://www.uptodate.com/contents/lentigo-maligna-clinical-manifestations-diagnosis-and-management/abstract/76\" class=\"nounderline abstract_t\">Cotter MA, McKenna JK, Bowen GM. Treatment of lentigo maligna with imiquimod before staged excision. Dermatol Surg 2008; 34:147.</a></li><li><a href=\"https://www.uptodate.com/contents/lentigo-maligna-clinical-manifestations-diagnosis-and-management/abstract/77\" class=\"nounderline abstract_t\">Fleming CJ, Bryden AM, Evans A, et al. A pilot study of treatment of lentigo maligna with 5% imiquimod cream. Br J Dermatol 2004; 151:485.</a></li><li><a href=\"https://www.uptodate.com/contents/lentigo-maligna-clinical-manifestations-diagnosis-and-management/abstract/78\" class=\"nounderline abstract_t\">Ly L, Kelly JW, O'Keefe R, et al. Efficacy of imiquimod cream, 5%, for lentigo maligna after complete excision: a study of 43 patients. Arch Dermatol 2011; 147:1191.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 13520 Version 10.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H652546\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H244299021\" id=\"outline-link-H244299021\">INTRODUCTION</a></li><li><a href=\"#H244299028\" id=\"outline-link-H244299028\">EPIDEMIOLOGY AND NATURAL HISTORY</a></li><li><a href=\"#H244299035\" id=\"outline-link-H244299035\">CLINICAL FEATURES</a></li><li><a href=\"#H2436682\" id=\"outline-link-H2436682\">DERMOSCOPIC FEATURES</a></li><li><a href=\"#H244299042\" id=\"outline-link-H244299042\">HISTOPATHOLOGIC FEATURES</a></li><li><a href=\"#H20157199\" id=\"outline-link-H20157199\">DIAGNOSIS</a><ul><li><a href=\"#H1146732\" id=\"outline-link-H1146732\">Clinical and dermoscopic examination</a></li><li><a href=\"#H60107460\" id=\"outline-link-H60107460\">Confocal scanning laser microscopy</a></li><li><a href=\"#H244299049\" id=\"outline-link-H244299049\">Biopsy and histologic examination</a></li></ul></li><li><a href=\"#H20157231\" id=\"outline-link-H20157231\">DIFFERENTIAL DIAGNOSIS</a></li><li><a href=\"#H244299056\" id=\"outline-link-H244299056\">TREATMENT</a><ul><li><a href=\"#H651881\" id=\"outline-link-H651881\">Overview</a></li><li><a href=\"#H651888\" id=\"outline-link-H651888\">Surgery</a><ul><li><a href=\"#H244299065\" id=\"outline-link-H244299065\">- Wide local excision</a></li><li><a href=\"#H190891\" id=\"outline-link-H190891\">- Staged excision</a></li><li><a href=\"#H190898\" id=\"outline-link-H190898\">- Mohs micrographic surgery</a></li></ul></li><li><a href=\"#H652399\" id=\"outline-link-H652399\">Nonsurgical therapies</a><ul><li><a href=\"#H244299072\" id=\"outline-link-H244299072\">- Radiation therapy</a></li><li><a href=\"#H244299079\" id=\"outline-link-H244299079\">- Topical imiquimod</a></li></ul></li></ul></li><li><a href=\"#H244299100\" id=\"outline-link-H244299100\">PROGNOSIS</a></li><li><a href=\"#H244299107\" id=\"outline-link-H244299107\">FOLLOW-UP</a></li><li><a href=\"#H652546\" id=\"outline-link-H652546\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DERM/13520|FIG\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"FIGURES\">FIGURES</a></div><ul><li><a href=\"image.htm?imageKey=DERM/71333\" class=\"graphic graphic_figure\">- Lentigo maligna staged excision</a></li></ul></li><li><div id=\"DERM/13520|PIC\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"PICTURES\">PICTURES</a></div><ul><li><a href=\"image.htm?imageKey=DERM/62052\" class=\"graphic graphic_picture\">- Lentigo maligna eyebrow</a></li><li><a href=\"image.htm?imageKey=DERM/59591\" class=\"graphic graphic_picture\">- Lentigo maligna nose</a></li><li><a href=\"image.htm?imageKey=DERM/68787\" class=\"graphic graphic_picture\">- Lentigo maligna cheek</a></li><li><a href=\"image.htm?imageKey=DERM/75238\" class=\"graphic graphic_picture\">- Lentigo maligna cheek 2</a></li><li><a href=\"image.htm?imageKey=DERM/77206\" class=\"graphic graphic_picture\">- Lentigo maligna periocular</a></li><li><a href=\"image.htm?imageKey=PC/62105\" class=\"graphic graphic_picture\">- New lentigo maligna melanoma</a></li><li><a href=\"image.htm?imageKey=DERM/57765\" class=\"graphic graphic_picture\">- Lentigo maligna melanoma 4</a></li><li><a href=\"image.htm?imageKey=DERM/74664\" class=\"graphic graphic_picture\">- Lentigo maligna melanoma 2</a></li><li><a href=\"image.htm?imageKey=DERM/54753\" class=\"graphic graphic_picture\">- Lentigo maligna melanoma 3</a></li><li><a href=\"image.htm?imageKey=DERM/63812\" class=\"graphic graphic_picture\">- Lentigo maligna melanoma dermoscopy 1</a></li><li><a href=\"image.htm?imageKey=DERM/68828\" class=\"graphic graphic_picture\">- Lentigo maligna dermoscopy</a></li><li><a href=\"image.htm?imageKey=DERM/60447\" class=\"graphic graphic_picture\">- Lentigo maligna histology</a></li><li><a href=\"image.htm?imageKey=ONC/53790\" class=\"graphic graphic_picture\">- Histol melanoma in situ lentigo</a></li><li><a href=\"image.htm?imageKey=DERM/81287\" class=\"graphic graphic_picture\">- Solar lentigines face</a></li><li><a href=\"image.htm?imageKey=DERM/61452\" class=\"graphic graphic_picture\">- Solar lentigo hand 2</a></li><li><a href=\"image.htm?imageKey=DERM/58445\" class=\"graphic graphic_picture\">- Seborrheic keratosis superficial</a></li><li><a href=\"image.htm?imageKey=ONC/73737\" class=\"graphic graphic_picture\">- Histol lentigo maligna melanoma</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=benign-pigmented-skin-lesions-other-than-melanocytic-nevi-moles\" class=\"medical medical_review\">Benign pigmented skin lesions other than melanocytic nevi (moles)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=dermoscopic-evaluation-of-skin-lesions\" class=\"medical medical_review\">Dermoscopic evaluation of skin lesions</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=dermoscopy-of-facial-lesions\" class=\"medical medical_review\">Dermoscopy of facial lesions</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=epidemiology-natural-history-and-diagnosis-of-actinic-keratosis\" class=\"medical medical_review\">Epidemiology, natural history, and diagnosis of actinic keratosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=melanoma-clinical-features-and-diagnosis\" class=\"medical medical_review\">Melanoma: Clinical features and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=mohs-surgery\" class=\"medical medical_review\">Mohs surgery</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-benign-lesions-of-the-skin\" class=\"medical medical_review\">Overview of benign lesions of the skin</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-dermoscopy\" class=\"medical medical_review\">Overview of dermoscopy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pathologic-characteristics-of-melanoma\" class=\"medical medical_review\">Pathologic characteristics of melanoma</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=radiation-therapy-in-the-management-of-melanoma\" class=\"medical medical_review\">Radiation therapy in the management of melanoma</a></li></ul></div></div>","javascript":null}